Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134758) titled 'Predictors of Belimumab Efficacy in Refractory Lupus Nephritis' on Oct. 20.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shanghai General Hospital
Condition:
Refractory Lupus Nephritis
Intervention:
6-Month Complete Renal Remission Group
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-01-19
Target Sample Size: 6-Month Complete Renal Remission Group; 6-Month Non-Complete Renal Remission Group:28;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=337250
Disclaimer: Curated by HT Syndication....